Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Ozeki, Michishige ^a   Fujita, Shu Ichi ^a   Kizawa, Shun ^a   Morita, Hideaki ^a   Sohmiya, Koichi ^a   Hoshiga, Masaaki ^a   Ishizaka, Nobukazu ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Chronic kidney disease; Fibroblast growth factor 23; Klotho

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; ALPHA KLOTHO PROTEIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FIBROBLAST GROWTH FACTOR 23; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; KLOTHO PROTEIN; LOOP DIURETIC AGENT; PHOSPHATE; SULFONYLUREA; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CARDIAC PATIENT; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CORRELATIONAL STUDY; CREATININE URINE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHOSPHATE BLOOD LEVEL; PROTEINURIA; RETROSPECTIVE STUDY; SERUM; URINALYSIS; BLOOD; CARDIOVASCULAR DISEASES; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; GLUCURONIDASE; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; RETROSPECTIVE STUDIES;

EID: 84907913274     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-147     Document Type: Article

References (42)

1. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. ADHR Consortium, Nat Genet 2000 26 3 345 348 10.1038/81664 11062477
2. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T, Proc Natl Acad Sci U S A 2001 98 11 6500 6505 10.1073/pnas.101545198 11344269
3. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI, Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, et al. Nature 1997 390 6655 45 51 10.1038/36285 9363890
4. Circulating alpha-klotho levels in CKD and relationship to progression. Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ, Shin DH, Doh FM, Koo HM, Ko KI, Kim CH, Oh HJ, Yoo TH, Kang SW, Han DS, Han SH, Am J Kidney Dis 2013 61 6 899 909 10.1053/j.ajkd.2013.01.024 23540260
5. Severely reduced production of klotho in human chronic renal failure kidney. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, Sugimura K, Kishimoto T, Kinoshita S, Kuroki T, Nabeshima Y, Biochem Biophys Res Commun 2001 280 4 1015 1020 10.1006/bbrc.2000.4226 11162628
6. Reduced renal alpha-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. Sakan H, Nakatani K, Asai O, Imura A, Tanaka T, Yoshimoto S, Iwamoto N, Kurumatani N, Iwano M, Nabeshima Y, Konishi N, Saito Y, PLoS One 2014 9 1 86301 10.1371/journal.pone.0086301 24466013
7. Regulation and function of the FGF23/klotho endocrine pathways. Martin A, David V, Quarles LD, Physiol Rev 2012 92 1 131 155 10.1152/physrev.00002.2011 22298654
8. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, de Filippi C, Wolf M, Circulation 2009 119 19 2545 2552 10.1161/CIRCULATIONAHA.108.844506 19414634
9. FGF23 induces left ventricular hypertrophy. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, et al. J Clin Invest 2011 121 11 4393 4408 10.1172/JCI46122 21985788
10. Reduced Klotho is associated with the presence and severity of coronary artery disease. Navarro-Gonzalez JF, Donate-Correa J, Muros De Fuentes M, Perez-Hernandez H, Martinez-Sanz R, Mora-Fernandez C, Heart 2014 100 1 34 40 10.1136/heartjnl-2013-304746 24165855
11. Associations between kidney function and subclinical cardiac abnormalities in CKD. Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A, Go AS, Shlipak MG, Chronic Renal Insufficiency Cohort (CRIC) Study Group, J Am Soc Nephrol 2012 23 10 1725 1734 10.1681/ASN.2012020145 22935481
12. Association between circulating fibroblast growth factor 23, alpha-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. Shibata K, Fujita S, Morita H, Okamoto Y, Sohmiya K, Hoshiga M, Ishizaka N, PLoS One 2013 8 9 73184 10.1371/journal.pone.0073184 24039882
13. Serum uric Acid is associated with left ventricular hypertrophy independent of serum parathyroid hormone in male cardiac patients. Fujita S, Okamoto Y, Shibata K, Morita H, Ito T, Sohmiya K, Hoshiga M, Ishizaka N, PLoS One 2013 8 12 82735 10.1371/journal.pone.0082735 24340056
14. Update on fibroblast growth factor 23 in chronic kidney disease. Wolf M, Kidney Int 2012 82 7 737 747 10.1038/ki.2012.176 22622492
15. Serum FGF23 levels in normal and disordered phosphorus homeostasis. Weber TJ, Liu S, Indridason OS, Quarles LD, J Bone Miner Res 2003 18 7 1227 1234 10.1359/jbmr.2003.18.7.1227 12854832
16. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Urena Torres P, Friedlander G, De Vernejoul MC, Silve C, Prie D, Kidney Int 2008 73 1 102 107 10.1038/sj.ki.5002622 17943081
17. Serum soluble alpha-klotho in hemodialysis patients. Yokoyama K, Imura A, Ohkido I, Maruyama Y, Yamazaki Y, Hasegawa H, Urae J, Sekino H, Nabeshima Y, Hosoya T, Clin Nephrol 2012 77 5 347 351 10.5414/CN107204 22551879
18. Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. Mathew J, Katz R, St John Sutton M, Dixit S, Gerstenfeld EP, Ghio S, Gold MR, Linde C, Shlipak MG, Deo R, Eur J Heart Fail 2012 14 12 1420 1428 10.1093/eurjhf/hfs135 22956574
19. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Palmieri V, Tracy RP, Roman MJ, Liu JE, Best LG, Bella JN, Robbins DC, Howard BV, Devereux RB, Diabetes Care 2003 26 10 2764 2769 10.2337/diacare.26.10.2764 14514577
20. Association of plasma soluble alpha-klotho with pro-endothelin-1 in patients with type 2 diabetes. Liu JJ, Liu S, Morgenthaler NG, Wong MD, Tavintharan S, Sum CF, Lim SC, Atherosclerosis 2014 233 2 415 418 10.1016/j.atherosclerosis.2014.01.024 24530772
21. Revised equations for estimated GFR from serum creatinine in Japan. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Am J Kidney Dis 2009 53 6 982 992 10.1053/j.ajkd.2008.12.034 19339088
22. Tests of phosphate reabsorption. Kenny AP, Glen AC, Lancet 1973 2 7821 158
23. Tumor-induced osteomalacia. Chong WH, Molinolo AA, Chen CC, Collins MT, Endocr Relat Cancer 2011 18 3 53 R77 10.1530/ERC-11-0006 21490240
24. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY, N Engl J Med 2004 351 13 1296 1305 10.1056/NEJMoa041031 15385656
25. Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study. Waheed S, Matsushita K, Sang Y, Hoogeveen R, Ballantyne C, Coresh J, Astor BC, Am J Kidney Dis 2012 60 2 207 216 10.1053/j.ajkd.2012.03.011 22537422
26. Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease. McQuarrie EP, Patel RK, Mark PB, Delles C, Connell J, Dargie HJ, Steedman T, Jardine AG, Nephrol Dial Transplant 2011 26 3 933 938 10.1093/ndt/gfq418 20624770
27. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Lundberg S, Qureshi AR, Olivecrona S, Gunnarsson I, Jacobson SH, Larsson TE, Clin J Am Soc Nephrol 2012 7 5 727 734 10.2215/CJN.10331011 22383747
28. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, Suzuki T, Amaki T, Mori I, Nakamura Y, Sato M, Nangaku M, Hirata Y, Nagai R, Hypertension 2002 39 4 838 843 10.1161/01.HYP.0000013734.33441.EA 11967236
29. Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. Zanchi C, Locatelli M, Benigni A, Corna D, Tomasoni S, Rottoli D, Gaspari F, Remuzzi G, Zoja C, PLoS One 2013 8 8 70775 10.1371/journal.pone.0070775 23967103
30. Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A. Kacso IM, Bondor CI, Kacso G, Clin Biochem 2012 45 16-17 1415 1420 22836100
31. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. Yang HC, Deleuze S, Zuo Y, Potthoff SA, Ma LJ, Fogo AB, J Am Soc Nephrol 2009 20 11 2380 2388 10.1681/ASN.2008111138 19797472
32. Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients. Lim SC, Liu JJ, Subramaniam T, Sum CF, J Renin Angiotensin Aldosterone Syst 2013 doi:10.1177/1470320313475905
33. Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. Karalliedde J, Maltese G, Hill B, Viberti G, Gnudi L, Clin J Am Soc Nephrol 2013 8 11 1899 1905 10.2215/CJN.02700313 23929932
34. Fibroblast growth factor 23 and Klotho serum levels in healthy children. Gkentzi D, Efthymiadou A, Kritikou D, Chrysis D, Bone 2014 66C 8 14
35. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Bai X, Miao D, Li J, Goltzman D, Karaplis AC, Endocrinology 2004 145 11 5269 5279 10.1210/en.2004-0233 15284207
36. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T, Biochem Biophys Res Commun 2004 314 2 409 414 10.1016/j.bbrc.2003.12.102 14733920
37. Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23. Ogura E, Kageyama K, Fukumoto S, Yagihashi N, Fukuda Y, Kikuchi T, Masuda M, Suda T, Intern Med 2008 47 7 637 641 10.2169/internalmedicine.47.0761 18379151
38. Relation between serum FGF-23 and phosphate or bone metabolism in adults. Komo T, J Osaka City Med Association 2007 56 35 41 [In Japanese]
39. Soluble klotho and autosomal dominant polycystic kidney disease. Pavik I, Jaeger P, Ebner L, Poster D, Krauer F, Kistler AD, Rentsch K, Andreisek G, Wagner CA, Devuyst O, Wüthrich RP, Schmid C, Serra AL, Clin J Am Soc Nephrol 2012 7 2 248 257 10.2215/CJN.09020911 22193235
40. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Spichtig D, Zhang H, Mohebbi N, Pavik I, Petzold K, Stange G, Saleh L, Edenhofer I, Segerer S, Biber J, Jaeger P, Serra AL, Wagner CA, Kidney Int 2014 85 6 1340 1350 10.1038/ki.2013.526 24402093
41. Fibroblast growth factor-23 and cardiovascular events in CKD. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M, Chronic Renal Insufficiency Cohort (CRIC) Study Investigators, J Am Soc Nephrol 2014 25 2 349 360 10.1681/ASN.2013050465 24158986
42. Associations of FGF-23 and sKlotho with Cardiovascular Outcomes among Patients with CKD Stages 2-4. Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, Floege J, Fliser D, Heine GH, Clin J Am Soc Nephrol 2014 9 6 1049 1058 10.2215/CJN.07870713 24677555